Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.44 |
| ▸ | EP300 | Q09472 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13374012 | 0.88 | CREBBP (0.57) | HCAR2KMT2ATSHRCREBBPEP300 | |
| SCHEMBL22029695 | 0.83 | CREBBP (0.42) | HCAR2KMT2ATSHRCREBBPEP300 | |
| SCHEMBL17785675 | 0.81 | CREBBP (0.47) | HCAR2KMT2ATSHRCREBBPEP300 | |
| SCHEMBL17785865 | 0.81 | CREBBP (0.44) | HCAR2KMT2ATSHRCREBBPEP300 | |
| SCHEMBL20818349 | 0.81 | CREBBP (0.44) | HCAR2KMT2ATSHRCREBBPEP300 | |
| SCHEMBL4761723 | 0.81 | CREBBP (0.47) | CREBBPEP300BRD4MAPK1 | |
| SCHEMBL30128141 | 0.81 | CYP2C19 (0.60) | HCAR2KMT2ATSHR | |
| SCHEMBL4870401 | 0.81 | NPC1 (0.55) | CREBBPEP300BRD4 | |
| SCHEMBL4792110 | 0.81 | ADORA1 (0.46) | HCAR2KMT2ATSHRCREBBPEP300 | |
| SCHEMBL18586765 | 0.78 | CREBBP (0.45) | CREBBPEP300BRD4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3036230-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | HCAR2 3535/4885KMT2A 1678/4885TSHR 3828/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | HCAR2 3979/4885KMT2A 1844/4885TSHR 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.